Skip to main content
. 2014 Aug 28;20(32):11347–11355. doi: 10.3748/wjg.v20.i32.11347

Table 1.

Clinical background of 5 patients with advanced gastric cancer

Age Sex TNM stage Histology of tumor Drug regimen of HIPEC Duration of HIPEC (min) ECOG HIPEC temperature (°C) Time of surgery (h) Following time (yr) and results
49 Male T4aN1M0 Poorly-differentiated adenocarcinoma 5-Fu cisplatin 60 1 43 3 1, alive
56 Male T3N2M0 Moderately-differentiated adenocarcinoma 5-Fu cisplatin 60 2 43 3.5 1.5, alive
67 Female T4N2M0 Poorly-differentiated adenocarcinoma 5-Fu cisplatin 60 0 43 3.8 1, dead
53 Male T3N1M0 Poorly-differentiated adenocarcinoma 5-Fu cisplatin 60 1 43 4 1.2, dead
62 Male T4bN0M0 Moderately-differentiated adenocarcinoma 5-Fu cisplatin 60 2 43 3 0.5, alive

ECOG: Eastern Cooperative Oncology Group; HIPEC: Hyperthermic intraperitoneal chemotherapy.